<DOC>
	<DOCNO>NCT02246478</DOCNO>
	<brief_summary>The objective study evaluate safety pharmacokinetic TAS-205 patient Duchenne Muscular Dystrophy .</brief_summary>
	<brief_title>A Study TAS-205 Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Duchenne Muscular Dystrophy ( DMD ) common fatal genetic disorder diagnose childhood , affect approximately 1 every 3500 life male birth . DMD patient suffer relentless decline muscle strength impairs ability walk breathing , result life wheelchairs loss upper body function . The objective study evaluate safety pharmacokinetic TAS-205 single multiple dos DMD patient . It also evaluate TAS-205 affect urinary excretion pharmacodynamic ( PD ) marker DMD patient .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Able give inform consent . If applicable , able give inform assent . Male &gt; = 5 year &lt; 16 year age . Bodyweight &gt; = 15.0 kg &lt; 75.0 kg . Phenotypic evidence DMD . Able take tablet . If take oral glucocorticosteroids significant change total daily dosage dose regimen enrollment . Confirmed urinary PD marker criterion . Able follow study protocol . Current diagnosis history drug allergy . A forced vital capacity ( FVC ) &lt; 50 % predict value . A left ventricular ejection fraction ( EF ) &lt; 50 % fractional shortening ( FS ) &lt; 25 % base echocardiogram ( ECHO ) . Ongoing immunosuppressive therapy ( corticosteroid ) . With severe disease hepatic disease , kidney disease others . With systemic allergic disease chronic inflammatory disease . Treated investigational agent within 90 day . Positive reaction hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody test ( HCV ) , human immunodeficiency virus ( HIV ) test .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>